A "CRISPR" non-viral manufacturing approach for CAR T cell therapies

Mol Ther. 2022 Nov 2;30(11):3338-3340. doi: 10.1016/j.ymthe.2022.09.022. Epub 2022 Oct 20.

Authors

Matthew J Cortese¹, Craig Sauter²

Affiliations

¹ Staff Physician & Assistant Professor of Oncology/Lymphoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Electronic address: [email protected].
² Director of Blood & Marrow Transplant (BMT), Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.

No abstract available

Publication types

Comment

MeSH terms

Gene Editing
Immunotherapy, Adoptive*
Receptors, Chimeric Antigen* / genetics

Substances

Receptors, Chimeric Antigen